Literature DB >> 7623960

Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice.

A R Dehpour1, H Farsam, M Azizabadi-Farahani.   

Abstract

Due to the claim that lithium (Li+) reduces morphine self-administration in dependent rats, the effects of acute and chronic Li+ treatments on naloxone-precipitated withdrawal syndrome and physical dependence development to morphine in mice chronically treated with morphine, were evaluated. Morphine dependency was induced by the ingestion of morphine through drinking water in increasing doses for 10 days. Physical dependence to morphine was observed by precipitating an abstinence syndrome with naloxone (2 mg/kg, i.p.). In the acute experiments, Li+ (1 and 10 mg/kg, i.p.) was administered 1 hr prior to challenge with naloxone to morphine-dependent mice whereas for chronic studies, mice received morphine concomitant with Li+ (1200 mg/l) as drinking fluid for 10 days. Results obtained indicate that acute Li+ administration significantly reduced the withdrawal signs, and we were unable to induce some degree of morphine dependency in co-administration of Li+ to mice receiving chronic morphine treatment as compared to chronic morphine administration alone. The present study revealed that even in mice with very much lower serum Li+ levels than the commonly accepted therapeutic range there was a significant reduction in the withdrawal signs. It has been shown that Li+ and morphine have diverse effects on the transmembrane signal control systems. The interaction of Li+ and morphine might be through these systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623960     DOI: 10.1016/0028-3908(94)00121-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania.

Authors:  Morgane Milienne-Petiot; James P Kesby; Mary Graves; Jordy van Enkhuizen; Svetlana Semenova; Arpi Minassian; Athina Markou; Mark A Geyer; Jared W Young
Journal:  Neuropharmacology       Date:  2016-10-11       Impact factor: 5.250

2.  Lithium reverses the effect of opioids on eNOS/nitric oxide pathway in human umbilical vein endothelial cells.

Authors:  Sadaf Nezamoleslami; Mohammad Sheibani; Faiza Mumtaz; Jamileh Esmaeili; Hamed Shafaroodi; Ahmad Reza Dehpour
Journal:  Mol Biol Rep       Date:  2020-09-04       Impact factor: 2.316

3.  Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features.

Authors:  Jordy van Enkhuizen; Morgane Milienne-Petiot; Mark A Geyer; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

4.  Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Authors:  John P Gustin; Bedri Karakas; Michele B Weiss; Abde M Abukhdeir; Josh Lauring; Joseph P Garay; David Cosgrove; Akina Tamaki; Hiroyuki Konishi; Yuko Konishi; Morassa Mohseni; Grace Wang; D Marc Rosen; Samuel R Denmeade; Michaela J Higgins; Michele I Vitolo; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

5.  The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.

Authors:  Chi-Tso Chiu; Lisa Scheuing; Guangping Liu; Hsiao-Mei Liao; Gabriel R Linares; Dora Lin; De-Maw Chuang
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-28       Impact factor: 5.176

6.  Lithium reverses mechanical allodynia through a mu opioid-dependent mechanism.

Authors:  Ivan Weinsanto; Jinane Mouheiche; Alexis Laux-Biehlmann; Maya Aouad; Tando Maduna; Nathalie Petit-Demoulière; Virginie Chavant; Pierrick Poisbeau; Pascal Darbon; Alexandre Charlet; Anne Giersch; Marie-Odile Parat; Yannick Goumon
Journal:  Mol Pain       Date:  2018-01-21       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.